Andere Kunden interessierten sich auch für
![Colorectal Cancer]( "Colorectal Cancer")
Colorectal Cancer84,99 €![Molecular Basis and Gene Therapies of Cystic Fibrosis]( "Molecular Basis and Gene Therapies of Cystic Fibrosis")
Molecular Basis and Gene Therapies of Cystic Fibrosis69,99 €![Pharmacy Practice and Administration 2.0]( "Pharmacy Practice and Administration 2.0")
Pharmacy Practice and Administration 2.073,99 €![Advances in Minimally Invasive Liver Resection for Cancer Therapies]( "Advances in Minimally Invasive Liver Resection for Cancer Therapies")
Advances in Minimally Invasive Liver Resection for Cancer Therapies73,99 €![New Therapies of Liver Diseases]( "New Therapies of Liver Diseases")
New Therapies of Liver Diseases82,99 €![Molecular and Cellular Mechanisms of Preeclampsia]( "Molecular and Cellular Mechanisms of Preeclampsia")
Molecular and Cellular Mechanisms of Preeclampsia115,99 €![The Effects of Mycotoxins on Human and Animal Health-a Special Focus on the Cellular and Molecular Mechanisms Responsible for Mycotoxin Toxicity]( "The Effects of Mycotoxins on Human and Animal Health-a Special Focus on the Cellular and Molecular Mechanisms Responsible for Mycotoxin Toxicity")
The Effects of Mycotoxins on Human and Animal Health-a Special Focus on the Cellular and Molecular Mechanisms Responsible for Mycotoxin Toxicity59,99 €
Colorectal cancer (CRC) is currently the third leading cause of cancer-related mortality. Transforming growth factor beta (TGF-¿) signaling has been associated with CRC growth and metastasis due to its involvement in proliferation, epithelial-to-mesenchymal transition (EMT), and angiogenesis. The TGF-¿ superfamily contains over forty members, including TGF-¿s, Nodal, Activin, and bone morphogenetic proteins (BMPs). Three types of TGF-¿ receptors (TGF¿Rs) have been identified: types 1, 2, and 3. After ligand binding, TGF-¿R2 recruits and phosphorylates TGF-¿R1, which, in turn, phosphorylates downstream SMAD (small mother against decapentaplegic) proteins. Phosphorylated SMAD4 translocates into the nucleus, where it activates the transcription of numerous target genes (including SERPINE1, LTBP2, CDKN1A, ARID3B, ATXN1, PTPRK, RAB6A, SMAD7, EHBP1, etc.), acting predominantly as a tumor suppressor gene. Interestingly, alterations in SMAD4 are frequent in metastatic CRC and, together with TGF-¿R2 gene mutations, have been reported as late events able to promote CRC progression. The study of the TGF-¿ pathway in metastatic CRC is challenging because of the great genetic heterogeneity of CRC. However, the increasing availability of targeted and whole-exome DNA sequencing techniques makes it possible to identify genetic mutations in complex, dynamic, and heterogeneous clinical contexts and make correlations with clinical outcomes.